Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition.
Hata, A.N., Niederst, M.J., Archibald, H.L., Gomez-Caraballo, M., Siddiqui, F.M., Mulvey, H.E., Maruvka, Y.E., Ji, F., Bhang, H.C., Radhakrishna, V.K., Siravegna, G., Hu, H., Raoof, S., Lockeerman, E., Kalsy, A., Lee, D., Keating, C.I., Ruddy, D.A., Damon, L.J., Crystal, A.S., Costa, C., Piotrowska, Z., Bardelli, A., Iafrate, A.J., Sadreyev, R.I., Stegmeier, F., Getz, G., Sequist, L.V., Faber, A.C. and Engelman, J.A.
Notes: This study investigated the reason why cancers become resistant to anti-cancer treatments over time. Non-small-cell lung cancers were cultured for weeks in the presence of EGF receptor inhibitors and resistant clones obtained based on a specific mutation in the EGF receptor. Clones that became resistant within 6 weeks were found to result from cells already containing the EGFR mutation. Clones taking about 24 weeks to become resistant evolved from the EGFR mutation. RealTime-Glo™ MT Cell Viability Assay was employed in several studies over a 10-week period to monitor proliferation (data presented in Supplementary Figures). Each week prior to media change, RealTime-Glo™ Assay reagents were added, incubated for 1 hour and luminescence measured. After 72-hour incubations, short-term viability was measured with the CellTiter-Glo® Luminescent Cell Viability Assay. (4699)
Expand Full Notes »